Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul:167:45-67.
doi: 10.1016/j.antiviral.2019.04.006. Epub 2019 Apr 8.

Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference

John H Beigel  1 , Hannah H Nam  2 , Peter L Adams  3 , Amy Krafft  4 , William L Ince  5 , Samer S El-Kamary  5 , Amy C Sims  6
Affiliations
Review

Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference

John H Beigel et al. Antiviral Res. 2019 Jul.

Abstract

The International Society for Influenza and other Respiratory Virus Diseases held its 6th Antiviral Group (isirv-AVG) conference in Rockville, Maryland, November 13-15, 2018. The three-day program was focused on therapeutics towards seasonal and pandemic influenza, respiratory syncytial virus, coronaviruses including MERS-CoV and SARS-CoV, human rhinovirus, and other respiratory viruses. Updates were presented on several influenza antivirals including baloxavir, CC-42344, VIS410, immunoglobulin, immune plasma, MHAA4549A, pimodivir (JNJ-63623872), umifenovir, and HA minibinders; RSV antivirals including presatovir (GS-5806), ziresovir (AK0529), lumicitabine (ALS-008176), JNJ-53718678, JNJ-64417184, and EDP-938; broad spectrum antivirals such as favipiravir, VH244, remdesivir, and EIDD-1931/EIDD-2801; and host directed strategies including nitazoxanide, eritoran, and diltiazem. Other topics included considerations of novel endpoints such as ordinal scales and patient reported outcomes (PRO), and study design issues, and other regulatory considerations for antiviral drug development. The aim of this report is to provide a summary of the presentations given at this meeting.

Keywords: Antiviral therapy; Coronavirus; Host-directed therapeutics; Influenza; Respiratory syncytial virus.

PubMed Disclaimer

References

    1. Agostini M.L., Andres E.L., Sims A.C., Graham R.L., Sheahan T.P., Lu X., Smith E.C., Case J.B., Feng J.Y., Jordan R., Ray A.S., Cihlar T., Siegel D., Mackman R.L., Clarke M.O., Baric R.S., Denison M.R. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9 - PMC - PubMed
    1. Al Ghamdi M., Alghamdi K.M., Ghandoora Y., Alzahrani A., Salah F., Alsulami A., Bawayan M.F., Vaidya D., Perl T.M., Sood G. Treatment outcomes for patients with middle eastern respiratory syndrome coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia. BMC Infect. Dis. 2016;16:174. - PMC - PubMed
    1. Al-Tawfiq J.A., Momattin H., Dib J., Memish Z.A. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int. J. Infect. Dis. 2014;20:42–46. - PMC - PubMed
    1. Anderson L.J., Parker R.A., Strikas R.L. Association between respiratory syncytial virus outbreaks and lower respiratory tract deaths of infants and young children. J. Infect. Dis. 1990;161:640–646. - PubMed
    1. Anthony S.J., Gilardi K., Menachery V.D., Goldstein T., Ssebide B., Mbabazi R., Navarrete-Macias I., Liang E., Wells H., Hicks A., Petrosov A., Byarugaba D.K., Debbink K., Dinnon K.H., Scobey T., Randell S.H., Yount B.L., Cranfield M., Johnson C.K., Baric R.S., Lipkin W.I., Mazet J.A. Further evidence for bats as the evolutionary source of Middle East respiratory syndrome coronavirus. mBio. 2017;8 - PMC - PubMed

Publication types

MeSH terms